{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:41Z","timestamp":1790727101184,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.annpat.2016.12.009","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T17:01:01Z","timestamp":1486141261000},"page":"61-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacit\u00e9 des inhibiteurs du checkpoint immunitaire PD-1\/PD-L1\u00a0et testing PD-L1\u00a0dans les cancers thoraciques"],"prefix":"10.1016","volume":"37","author":[{"given":"Micha\u00ebl","family":"Duruisseaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rouquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Cazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2016.12.009_bib0335","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1\u00a0cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2016.12.009_bib0340","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0345","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0350","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1\u00a0promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0355","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","article-title":"B7-H1\u00a0is expressed by human endothelial cells and suppresses T cell cytokine synthesis","volume":"169","author":"Mazanet","year":"2002","journal-title":"J Immunol B"},{"key":"10.1016\/j.annpat.2016.12.009_bib0360","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0365","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0370","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0375","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0380","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annpat.2016.12.009_bib0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0390","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0395","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0400","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0405","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0410","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3\u00a0trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annpat.2016.12.009_bib0415","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0420","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0425","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0430","article-title":"CheckMate 026: a phase 3\u00a0trial of nivolumab vs. investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage\u00a0IV\/recurrent programmed death ligand 1 (PD-L1)\u00a0\u2212\u00a0positive NSCLC","author":"Socinski","year":"2016","journal-title":"ESMO"},{"key":"10.1016\/j.annpat.2016.12.009_bib0435","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0440","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2\u00a0randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annpat.2016.12.009_bib0445","article-title":"Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L\/3L NSCLC","author":"Barlesi","year":"2016","journal-title":"ESMO"},{"key":"10.1016\/j.annpat.2016.12.009_bib0450","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0455","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1\u00a0pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annpat.2016.12.009_bib0460","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1\u00a0Expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2016.12.009_bib0465","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/gcc.22365","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274)\u00a0\u2013\u00a0associations with gene expression, mutational load and survival","volume":"55","author":"Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0470","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1\u00a0and programmed cell death-ligand 1\u00a0and 2\u00a0expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1\u00a0blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.annpat.2016.12.009_bib0480","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annpat.2016.12.009_bib0485","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.humimm.2014.01.006","article-title":"MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1\u00a0over-expression in advanced colorectal cancer","volume":"75","author":"Zhu","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0490","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CJI.0b013e31802e085a","article-title":"The new B7s: playing a pivotal role in tumor immunity","volume":"30","author":"Flies","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.annpat.2016.12.009_bib0495","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1\u00a0is upregulated by simultaneous amplification of\u00a0the PD-L1\u00a0and JAK2\u00a0genes in non-small cell lung\u00a0cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0500","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1158\/0008-5472.CAN-14-2598","article-title":"Mechanisms of hypoxia-mediated immune escape in cancer","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2016.12.009_bib0505","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1\u00a0pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0510","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0515","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","article-title":"Clinicopathological analysis of PD-L1\u00a0and PD-L2\u00a0expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers","volume":"88","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0520","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1\u00a0status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1\u00a0therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0525","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1\u00a0expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0530","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-14-0234","article-title":"Assessing the effects of concurrent versus sequential cisplatin\/radiotherapy on immune status in lung tumor-bearing C57BL\/6\u00a0mice","volume":"3","author":"Kao","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annpat.2016.12.009_bib0535","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.annpat.2016.12.009_bib0540","first-page":"3025","article-title":"PD-L1\u00a0expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age","volume":"34","author":"Midha","year":"2016","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.annpat.2016.12.009_bib0545","article-title":"A quantitative comparison of antibodies to programmed cell death 1\u00a0ligand 1","author":"Gaule","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0550","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13000-016-0494-2","article-title":"Quantitative and qualitative characterization of two PD-L1\u00a0clones: SP263\u00a0and E1L3\u00a0N","volume":"11","author":"Smith","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0555","article-title":"Validated programmed cell death ligand 1\u00a0immunohistochemistry assays (E1L3\u00a0N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system","author":"Schats","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.annpat.2016.12.009_bib0560","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1\u00a0antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annpat.2016.12.009_bib0565","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1\u00a0immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0570","first-page":"462","article-title":"An H-X, Wu J-X. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis","volume":"7","author":"Pan","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.annpat.2016.12.009_bib0575","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.2147\/OTT.S91469","article-title":"Prognostic value of programmed cell death-ligand 1\u00a0expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis","volume":"8","author":"Zhong","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annpat.2016.12.009_bib0580","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994\u00a0and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.annpat.2016.12.009_bib0585","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11864-011-0149-1","article-title":"Novel targeted therapies and vaccination strategies for mesothelioma","volume":"12","author":"Bagia","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0590","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2016.12.009_bib0595","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0600","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1\u00a0expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0605","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.7589","article-title":"T-cell inflamed phenotype and PDL1\u00a0expression in malignant mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0610","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1\u00a0ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.annpat.2016.12.009_bib0615","unstructured":"Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma n.d. 2016 http:\/\/www.aacr.org\/Newsroom\/pages\/News-Release-Detail.aspx?ItemID=696#.V_JnlNwXw_U.(accessed October 3, 2016)."},{"key":"10.1016\/j.annpat.2016.12.009_bib0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1\u00a0and TLR3\u00a0in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0625","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Cedr\u00e9s","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0630","first-page":"8518","article-title":"Correlation of PD-L1\u00a0expression with immune cell infiltrates, genome-wide copy number aberrations and survival in mesothelioma","volume":"34","author":"Thapa","year":"2016","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.annpat.2016.12.009_bib0635","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant pleural mesothelioma. From the international mesothelioma interest group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.annpat.2016.12.009_bib0640","first-page":"34","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity and PD-L1\u00a0expression","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0645","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1\u00a0in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0650","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1\u00a0staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annpat.2016.12.009_bib0655","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annpat.2016.12.009_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to pembrolizumab in a patient with relapsing thymoma","author":"Zander","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649816301766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649816301766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:35:11Z","timestamp":1759332911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649816301766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0242649816301766"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2016.12.009","relation":{},"ISSN":["0242-6498"],"issn-type":[{"value":"0242-6498","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 des inhibiteurs du checkpoint immunitaire PD-1\/PD-L1\u00a0et testing PD-L1\u00a0dans les cancers thoraciques","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}